Bipolar Disorder - A Pipeline Analysis Report by Technavio
May. 16, 2018
LONDON--(BUSINESS WIRE)--May 16, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat bipolar disorder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005601/en/
Technavio has published a new pipeline analysis report on the global bipolar disorder market, including a detailed study of the pipeline molecules. (Photo: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the upcoming years.
Bipolar disorder - market overview
is a mental disorder that causes extreme shifts in mood, energy, and activity levels. It is also known as manic depression as elevated mood swings are called mania or hypomania. Mania and hypomania differ based on the severity and the presence of psychosis.
According to a senior analyst at Technavio for , “Bipolar disorder is a long-lasting condition that can be with regular treatment plans. Bipolar disorder can be characterized into bipolar I, bipolar II, and cyclothymia. There are many other bipolar disorders that belong to a group that does not follow any particular pattern.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Bipolar disorder segmentation
This market research report segments the market based on therapies employed that includes (monotherapy, combination therapy, and unknown), RoA (oral and undisclosed), therapeutic modalities (small molecules, and undefined), targets (dopamine receptor and 5-HT2A receptor; 5-HT2A and NMDA receptors; 5-HT1A, D2, and 5-HT2A receptors; glutathione peroxidase; norepinephrine-dopamine reuptake, 5HT1A; G protein-coupled receptors, and undisclosed), drugs under development (discovery, pre-clinical, phase I, phase II, phase II/III, and phase III), indications coverage (bipolar depression, bipolar disorder, and bipolar I disorder), and recruitment status (not yet recruiting, recruiting, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005601/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/16/2018 06:38 AM/DISC: 05/16/2018 06:38 AM